CYP2C19 Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?

被引：3
作者：
Maamari, Dimitri J. [1 ,5 ]
Jaffer, Farouc A. [2 ,3 ,4 ]
Khera, Amit, V [1 ,2 ,4 ,5 ]
Fahed, Akl C. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Cardiol Div, Boston, MA 02114 USA
[4] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
[5] Broad Inst MIT & Harvard, Cardiovasc Dis Initiat, Cambridge, MA 02142 USA
来源：
CIRCULATION | 2022年 / 145卷 / 10期
基金：
美国国家卫生研究院;
关键词：
anticoagulants; cytochrome P-450 CYP2C19; pharmacogenetics; precision medicine;
D O I：
10.1161/CIRCULATIONAHA.121.057028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：721 / 723
页数：3
相关论文
共 5 条
  • [1] Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention A North American Perspective: 2021 Update
    Angiolillo, Dominick J.
    Bhatt, Deepak L.
    Cannon, Christopher P.
    Eikelboom, John W.
    Gibson, C. Michael
    Goodman, Shaun G.
    Granger, Christopher B.
    Holmes, David R.
    Lopes, Renato D.
    Mehran, Roxana
    Moliterno, David J.
    Price, Matthew J.
    Saw, Jacqueline
    Tanguay, Jean-Francois
    Faxon, David P.
    [J]. CIRCULATION, 2021, 143 (06) : 583 - 596
  • [2] Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis Insights From the REAL-ST Registry
    Kuramitsu, Shoichi
    Ohya, Masanobu
    Shinozaki, Tomohiro
    Otake, Hiromasa
    Horie, Kazunori
    Kawamoto, Hiroyoshi
    Yamanaka, Futoshi
    Natsuaki, Masahiro
    Shiomi, Hiroki
    Nakazawa, Gaku
    Ando, Kenji
    Kadota, Kazushige
    Saito, Shigeru
    Kimura, Takeshi
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (06)
  • [3] Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
    Pereira, Naveen L.
    Farkouh, Michael E.
    So, Derek
    Lennon, Ryan
    Geller, Nancy
    Mathew, Verghese
    Bell, Malcolm
    Bae, Jang-Ho
    Jeong, Myung Ho
    Chavez, Ivan
    Gordon, Paul
    Abbott, J. Dawn
    Cagin, Charles
    Baudhuin, Linnea
    Fu, Yi-Ping
    Goodman, Shaun G.
    Hasan, Ahmed
    Iturriaga, Erin
    Lerman, Amir
    Sidhu, Mandeep
    Tanguay, Jean-Francois
    Wang, Liewei
    Weinshilboum, Richard
    Welsh, Robert
    Rosenberg, Yves
    Bailey, Kent
    Rihal, Charanjit
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (08): : 761 - 771
  • [4] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
    Scott, S. A.
    Sangkuhl, K.
    Gardner, E. E.
    Stein, C. M.
    Hulot, J-S
    Johnson, J. A.
    Roden, D. M.
    Klein, T. E.
    Shuldiner, A. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) : 328 - 332
  • [5] Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention
    Secemsky, Eric A.
    Butala, Neel M.
    Kartoun, Uri
    Mahmood, Sadiqa
    Wasfy, Jason H.
    Kennedy, Kevin F.
    Shaw, Stanley Y.
    Yeh, Robert W.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (10):
1